The positive topline data from the PACIFIC Study is directly related to Longboard Pharmaceuticals' potential future revenues and market position. Such clinical milestones are critical for biotech companies and can significantly influence investor sentiment and stock price. Given the nature of the news and the market's typical reaction to positive clinical trial results, a short-term increase in stock price is likely.